Comments on: Ipsen and Servier Announce Initial Phase 1/2 Clinical Data Evaluating Liposomal Irinotecan (ONIVYDE®) as an Investigational First-line Treatment for Metastatic Pancreatic Cancer at ESMO 21st World Congress on Gastrointestinal Cancer

Comments on: Ipsen and Servier Announce Initial Phase 1/2 Clinical Data Evaluating Liposomal Irinotecan (ONIVYDE®) as an Investigational First-line Treatment for Metastatic Pancreatic Cancer at ESMO 21st World Congress on Gastrointestinal Cancer https://www.novumpr.nl/2019/07/05/ipsen-and-servier-announce-initial-phase-1-2-clinical-data-evaluating-liposomal-irinotecan-onivyde-as-an-investigational-first-line-treatment-for-metastatic-pancreatic-cancer-at-esmo-21st-worl/?utm_source=rss&utm_medium=rss&utm_campaign=ipsen-and-servier-announce-initial-phase-1-2-clinical-data-evaluating-liposomal-irinotecan-onivyde-as-an-investigational-first-line-treatment-for-metastatic-pancreatic-cancer-at-esmo-21st-worl NovumPR press releases Fri, 05 Jul 2019 08:46:40 +0000 hourly 1 https://wordpress.org/?v=6.8.3